Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Algert Global LLC reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 8.6% in ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.05 which represents a slight increase of $2.26 or 12.03% from the prior close of $18.79. The stock ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

TD Cowen analyst Brendan Smith has maintained their bullish stance on ARWR stock, giving a Buy rating on November 20.Don't Miss our Black ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...